Search results for "POSTPARTUM HEMORRHAGE"

showing 6 items of 6 documents

Successful treatment of life-threatening bleeding after cesarean section with recombinant activated factor VII.

2006

Hemorrhagic shock developed in a 29-year-old nullipara without coagulopathy after emergency caesarean section. Treatment with uterotonic drugs, prostaglandins, and conservative procedures with transfusion of packed red cells and fresh-frozen plasma failed to control the diffuse vaginal and uterine bleeding. Finally an intravenous bolus injection of 90 μg/kg recombinant activated factor VII (rFVIIa, NovoSeven®, Novo Nordisk A/S, Bagsvaerd, Denmark), was given and showed success within 20 minutes after administration, without any side effects.

Adultmedicine.medical_specialtyPacked Red CellsCritical IllnessUterotonicFactor VIIa030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicinelawPregnancyActivated factor VIImedicineCoagulopathyHumans030212 general & internal medicinepostpartum bleedingbusiness.industryCesarean SectionPostpartum HemorrhageUterine bleedingHematologyGeneral MedicineFactor VIImedicine.diseaseRecombinant ProteinsSurgeryTreatment OutcomeAnesthesiaHemorrhagic shockRecombinant DNAFemalebusinessClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Intramuscular tranexamic acid

2021

For many anaesthetists around the world, the mere mention of the word ‘pharmacokinetics’ is sufficient to make their eyes glaze over and their attention wander. Pharmacokinetics is seen as an art that is as obscure and esoteric as the art of divination (prediction) practiced by the likes of Professor Sybille Trelawny 1 but that has varying and mostly limited relevance to clinical practice. Although this hyperbole may have elements of truth, it is a fact that pharmacokinetic data are the essential foundation upon which rational drug dosing guidelines are developed for all drugs.

Clinical pharmacologybusiness.industryMORTALITYPOSTPARTUM HEMORRHAGEPostpartum haemorrhageAntifibrinolytic Agentstranexamic acidlaw.inventionAnesthesiology and Pain MedicinetraumaPharmacokineticsPregnancylawpostpartum haemorrhageAnesthesiaManagement of Technology and InnovationmedicineHumansFemaleclinical pharmacologybusinesspharmacokineticsTranexamic acidmedicine.drugBritish Journal of Anaesthesia
researchProduct

Accuracy of blood transfusion in postpartum hemorrhage to assess maternal morbidity.

2012

International audience; OBJECTIVE: To measure the accuracy of blood transfusion (timing and number of blood units) in postpartum hemorrhage (PPH) in a perinatal network. STUDY DESIGN: (1) The ANONYMAT software system was used for anonymization and linkage of two large stand-alone databases, the Burgundy Perinatal Network (BPN) and the National Blood Centre (EFS) databases, which contain, respectively, clinical data from hospital discharges and information concerning any blood transfusion in France (considered as the gold standard database for identifying any transfusion). (2) Identification of prescriptions of at least one red blood cell (RBC) unit at the day of delivery (≥22 weeks) and up …

PediatricsBlood transfusionmedicine.medical_treatment0302 clinical medicineMESH: PregnancyBlood productPregnancyPerinatal networkMESH : Blood Transfusion[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : Female030212 general & internal medicineMESH : Obstetrics030219 obstetrics & reproductive medicineObstetricsMedical recordObstetrics and GynecologyMESH: Postpartum HemorrhageMESH: Predictive Value of Tests3. Good healthObstetricsBlood units[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleFranceMESH : Sensitivity and SpecificityMESH: Obstetricsmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMaternal morbidityMESH: Blood TransfusionMESH : Postpartum HemorrhageSensitivity and Specificity03 medical and health sciencesPredictive Value of TestsmedicineHumansBlood TransfusionMESH : Predictive Value of TestsMedical prescriptionMESH : FranceMESH: Humansbusiness.industryPostpartum HemorrhageMESH : HumansGold standard (test)MESH: Sensitivity and SpecificityMESH: FranceMESH : PregnancyReproductive MedicinebusinessMESH: Female
researchProduct

Tranexamic acid for the prevention of blood loss after cesarean section: an updated systematic review and meta-analysis of randomized controlled tria…

2023

Objective: Tranexamic acid (TXA) is a cost-effective intervention for the prevention of postpartum hemorrhage (PPH) in women undergoing cesarean section but the evidence to support its use is conflicting. We conducted this meta-analysis to evaluate the efficacy and safety of TXA in low- and high-risk cesarean deliveries. Data sources: We searched MEDLINE (via PubMed), Embase, the Cochrane Library, ClinicalTrials.gov, and WHO International Clinical Trials Registry Platform (ICTRP) portal from inception to April 2022 (updated October 2022 and February 2023) with no language restrictions. Additionally, grey literature sources were also explored. Study eligibility criteria: All randomized contr…

Postpartum hemorrhageAntifibrinolyticMeta-analysiTranexamic acid.Cesarean sectionSettore MED/40 - Ginecologia E Ostetricia
researchProduct

Postpartum Hemorrhage: Conservative Treatments

2023

Postpartum hemorrhage (PPH) is an obstetric emergency representing the first cause of obstetric mortality and a frequent cause of severe maternal morbidity. It can complicate vaginal or cesarean deliveries and accounts for 25% of all maternal deaths worldwide, as reported by the World Health Organization (WHO). Primary PPH is defined as blood loss from the genital tract of at least 500 ml after vaginal or 1000 ml following cesarean delivery within 24 h postpartum, whereas secondary PPH is defined as any significant bleeding from the birth canal occurring between 24 h and 12 weeks postnatally. Uterine atony is reported as the main cause of PPH and accounts for 75%–90% of primary PPH. When ut…

Postpartum hemorrhageUterotonic agentUterine tamponade procedureVascular ligation.Selective arterial embolizationUterine compression sutureUterine atonySettore MED/40 - Ginecologia E Ostetricia
researchProduct

Advantages and limitations of using national administrative data on obstetric blood transfusions to estimate the frequency of obstetric hemorrhages

2013

International audience; BACKGROUND: Obstetric hemorrhages are a frequent cause of maternal death all over the world, but are not routinely monitored. Health systems administrative databases could be used for this purpose, but data quality needs to be assessed. OBJECTIVES: Using blood transfusion data recorded in administrative databases to estimate the frequency of obstetric hemorrhages. Research design A population-based study. Subjects Validation sub-sample: all mothers who gave birth in a French region in 2006-07 (35 123 pregnancies). Main study: all mothers who gave birth in France in 2006-07 (1 629 537 pregnancies). METHOD: Linkage and comparison of administrative data on blood transfu…

Research designBlood transfusionmedicine.medical_treatmentPopulation[ SDV.MHEP.PED ] Life Sciences [q-bio]/Human health and pathology/Pediatrics03 medical and health sciences0302 clinical medicinePregnancymedicineHumansBlood Transfusion030212 general & internal medicineeducationeducation.field_of_studyPregnancy[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics030219 obstetrics & reproductive medicinebusiness.industryData CollectionPostpartum HemorrhageInfant NewbornPublic Health Environmental and Occupational HealthInfantReproducibility of ResultsGeneral Medicinemedicine.diseaseNewborn3. Good healthLogistic ModelsDatabases as TopicData qualityFeasibility StudiesMaternal deathFemaleMedical emergencyFrancebusinessDatabases as TopicHealthcare system
researchProduct